503A vs. 503B Compounding: The Definitive Explainer

If you work in medical aesthetics, weight management, or any field that uses compounded medications, you have heard the terms "503A" and "503B." But many providers — even experienced ones — are fuzzy on exactly what the distinction means and why it matters.

This post is the definitive explainer. By the end, you will understand the two tracks clearly enough to make informed decisions about your supply chain and your compliance posture.

The 503A/503B framework was created by the Drug Quality and Security Act (DQSA), signed into law in November 2013. The DQSA was passed in response to the 2012 New England Compounding Center (NECC) meningitis outbreak, which killed 64 people and was linked to contaminated compounded steroids.

Before the DQSA, compounding was regulated primarily by state boards of pharmacy, with limited federal oversight. The NECC disaster exposed the gaps in that system. The DQSA created a new federal framework with two distinct tracks.

Section 503A governs what the law calls "traditional compounding pharmacies." Here is what defines 503A:

Patient-specific: Every preparation must be made for an individually identified patient based on a valid prescription from a licensed practitioner. You cannot make batches in advance for general use.

Valid prescription required: A licensed prescriber must issue a prescription for a named patient. The prescription must be based on a valid patient-prescriber relationship.

State-regulated: 503A pharmacies are primarily regulated by state boards of pharmacy. The FDA has some oversight authority but state boards are the primary regulators.

Not subject to CGMP: 503A pharmacies are not required to follow FDA's Current Good Manufacturing Practice (CGMP) regulations. They must follow USP compounding standards (USP <795>, <797>, <800>) and state board requirements.

Cannot wholesale: 503A pharmacies cannot sell compounded preparations to other pharmacies or healthcare facilities for resale. They can only dispense to the patient named on the prescription or to the prescriber for office use (with limitations).

Cannot compound essentially a copy: 503A pharmacies generally cannot compound a preparation that is essentially a copy of a commercially available drug product.

• Individual patients with prescriptions
• Medical practices ordering patient-specific preparations
• Prescribers ordering for specific patients they have evaluated

For patient-specific prescribing, 503A is the appropriate track. It allows for true customization — the exact strength, form, and formulation the prescriber determines is appropriate for that specific patient.

Section 503B created a new category of compounder: the "outsourcing facility." Here is what defines 503B:

No patient-specific prescription required: 503B facilities can produce large batches of compounded preparations without patient-specific prescriptions. They can produce for "office use" — stocking by healthcare facilities for administration to patients.

FDA-registered: 503B facilities must register with the FDA as outsourcing facilities. This is a federal registration, not just a state license.

FDA-inspected: 503B facilities are subject to FDA inspection, similar to pharmaceutical manufacturers.

CGMP-compliant: 503B facilities must follow FDA's Current Good Manufacturing Practice regulations. This is a significantly higher standard than USP compounding standards alone.

Can supply healthcare facilities: 503B facilities can sell compounded preparations to hospitals, clinics, physician offices, and other healthcare facilities for office use.

Shortage-based compounding: 503B facilities can compound drugs on the FDA's shortage list, which is the legal basis for much of the compounded GLP-1 market.

• Hospitals and health systems stocking compounded preparations
• Physician offices ordering for office-use administration
• Medical spas and weight loss clinics ordering GLP-1s for office use
• Non-sterile pharmacies ordering bulk compounded products

For high-volume practices that want to stock compounded preparations without patient-specific prescriptions for each unit, 503B is the appropriate track. The CGMP manufacturing standards also support extended BUD dates.

Use 503A when:

• You are prescribing for individual patients with specific needs
• You need a custom formulation not available from a 503B facility
• Your state requires patient-specific prescriptions for the compounds you use

Use 503B when:

• You want to stock compounded preparations for office use
• You need extended BUD dates for inventory management
• You are ordering at high volume and want CGMP-manufactured products

Use both when:

• You have a mix of patient-specific and office-use needs
• You want maximum flexibility in your supply chain

MedClinic Partners operates in both tracks, giving our clients the flexibility to use whichever is appropriate for their specific situation.

Request portal access →

For licensed medical providers only. This content is for informational purposes only and does not constitute legal advice.